RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells
暂无分享,去创建一个
Keiji Mashimo | T. Takeda | Ryota Asano | Minami Jinushi | M. Imano | T. Satou | Katsuhiko Sakaguchi | S. Nishida | M. Tsubaki